 Incyte stock tumbled below its 200-day line Tuesday after sales of the companys new skin treatment lagged second-quarter expectations. The post Incyte Posts Strong Quarter For Cancer Drug; Heres Why Shares Crumbled appeared first on Investors Business Daily. 